SCHEMBL29601629

SCHEMBL29601629

CCC(Br)C(=O)c1ccccn1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 1/20 0.66
ALDH1A1 P00352 3/20 0.52
CES2 O00748 1/20 0.50
CES1 P23141 1/20 0.50
L3MBTL1 Q9Y468 3/20 0.48
LMNA P02545 2/20 0.48
NAPRT Q6XQN6 1/20 0.48
P4HTM Q9NXG6 1/20 0.48
KMT2A Q03164 1/20 0.44
KDM4E B2RXH2 4/20 0.44
HTT P42858 2/20 0.44
NPC1 O15118 2/20 0.43
PKM P14618 2/20 0.43
RAB9A P51151 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
MITF O75030 1/20 0.43
GRM4 Q14833 1/20 0.43
CTNNB1 P35222 1/20 0.43
WNT3A P56704 1/20 0.43
GAA P10253 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15993270 1.00 GSK3B (0.66) GSK3BALDH1A1CES2CES1L3MBTL1
SCHEMBL6197746 0.84 GSK3B (0.62) GSK3BALDH1A1CES2CES1L3MBTL1
SCHEMBL19782864 0.83 GSK3B (0.57) GSK3BALDH1A1CES2CES1L3MBTL1
SCHEMBL15993216 0.83 GSK3B (0.57) GSK3BALDH1A1CES2CES1L3MBTL1
SCHEMBL19333994 0.82 GSK3B (0.59) GSK3BALDH1A1CES2CES1L3MBTL1
SCHEMBL15993028 0.82 GSK3B (0.55) GSK3BALDH1A1CES2CES1L3MBTL1
SCHEMBL19578168 0.81 GSK3B (0.58) GSK3BALDH1A1CES2CES1L3MBTL1
SCHEMBL7277861 0.81 GSK3B (0.58) GSK3BALDH1A1CES2CES1L3MBTL1
SCHEMBL19782876 0.81 GSK3B (0.54) GSK3BALDH1A1CES2CES1L3MBTL1
SCHEMBL5312170 0.80 GSK3B (0.72) GSK3BALDH1A1CES2CES1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4232449-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES Celgene Corporation (US) 2023-08-30 EP disclosed
CN-116547282-A Heterocyclic compounds and their use for the treatment of helminth infections and diseases 新基公司 2023-08-04 CN disclosed
WO-2022087326-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES CELGENE CORPORATION (US) 2022-04-28 WO disclosed